Headquartered in Parma since 1935, today we are an international company with more 80 years of experience and a strong focus ... on research, development, production and the commercialization of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas. With a turnover of more than €1.4 billion sales we are among the top 50 pharmaceutical companies in the world. Our production sites are in Parma, Italy, Blois (France) and Santana De Parnaiba (Brazil). The R&D centers in Parma (Italy), Paris (France), Cary (USA), Chippenham (UK) and the R&D team from the acquired Danish company Zymenex, integrate their efforts to advance Chiesi's pre-clinical, clinical and registration programs. We export to more than 70 countries with a direct presence in 26. The Chiesi Group employs approximately 4,500 people, 560 of whom are dedicated to R&D activities and 700 of whom work at production sites. Our aim is to be recognized as a research-focused international Group, able to develop and commercialize innovative pharmaceutical solutions to improve the quality of human life. We wish to maintain a high-quality entrepreneurial team characterized by self-confidence and a collaborative spirit. Our goal is to combine commitment to results with integrity, operating in a socially and environmentally responsible manner. Chiesi Greece was established in 1998 by twelve people with vision, courage and enthusiasm. 19 years later, Chiesi Greece, with already more than five times its staff and more than twenty times its sales, is a well-organized company with a strong presence in the Greek pharmaceutical market, with high rates of growth that are a serious asset for an even better future. Chiesi Greece invests in its people, relies on them and supports them. It understands their needs and rewards their efforts. It understands the difficulties they face and helps them overcome them. Through continuous training, it extends their cognitive level and improves the read more